Solvias, a European company, is opening a biotech facility in Morrisville and plans to eventually hire well above 100 workers.
Triangle Business Journal’s Post
More Relevant Posts
-
💡 In Benchling's webinar, delve into the challenges of modern biopharma development. The speakers, Areef Jetha and Justin De La Cruz, PhD will guide you through overcoming hurdles in cell line development, upstream and downstream processing, and analytical operations for modern drug modalities. 📌 Watch the full webinar here: https://buff.ly/3tdircg #CellCulture #ProcessDevelopment #LaboratoryTechnology #CellLineDevelopment
To view or add a comment, sign in
-
-
Known for its abundant forests, smorgasbords, and, of course, the famed Europop group ABBA, Sweden has a thriving economy that largely depends on manufacturing and exports. Plus, the country’s life science sector recorded a net turnover of almost SEK 365 billion ($34 billion) in 2020 – an increase of just over SEK 158 billion ($14.8 billion) since 2014 – and it is still ever-growing. Labiotech.eu discusses eight #biotech companies in Sweden spearheading the country’s biotech scene. * Amferia * Anocca * Aprea Therapeutics * Asgard Therapeutics * BioInvent International AB * Diamyd Medical * Hamlet BioPharma * Modus Therapeutics Holding AB Find out more via https://lnkd.in/ew7FAXYQ
To view or add a comment, sign in
-
-
Recursion, a biotech firm which uses artificial intelligence to discover new drug candidates to acquire Exscientia, a technology-driven drug design and development company, for $688m. “We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers. Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started," Chris Gibson, Recursion Co-Founder and CEO. Exscientia (led by Dave H., Ben Taylor and Dan Ireland) is advised by Centerview Partners and A&O Shearman. Recursion (led by Chris Gibson, Michael Secora PhD and Nathan Hatfield) is advised by Allen & Company LLC. and Wilson Sonsini Goodrich & Rosati. #MergersAcquisitionsDivestitures #Pharmaceuticals #Biotechnology
Recursion Pharmaceuticals to acquire Exscientia for $688m.
app.mergerlinks.com
To view or add a comment, sign in
-
Be sure to catch Wheeler's Chief Development Officer Brian R. Berquist, Ph.D. on ATUM's latest webinar where they will be taking a deep dive into many of the technologies, methods, and models that we utilize to ameliorate the translational gap in biologics development. #webinar #biologics #discovery
🔬 Don't miss ATUM's upcoming webinar with Wheeler Bio, Inc. exploring innovative strategies for biologics discovery and development! Discover how leveraging cutting-edge tools, technologies, and machine learning can overcome scaling-up hurdles. Learn from Oren Beske, Ph.D., Amalgamator of Business & Biology at ATUM, and Brian R. Berquist, Ph.D., Chief Development Officer at Wheeler Bio, about the combined use of an open-source platform and hybrid-mechanistic process model, enabling well-controlled SBCs, high titers, and process robustness. Understand the benefits of SBC-based platforms in reducing early development costs and timelines. ➡️ REGISTER HERE: https://hubs.li/Q02sBs630 #ClinicalDevelopment #PreClinical #BiologicsManufacturing #CellAndGeneTherapies
Reimagining the Translation from Biologics Discovery to Development
xtalks.com
To view or add a comment, sign in
-
9 Steps to a Successful Lab Move. You’ve seen the signs. You’ve heard the whispers. Just like summer, a lab move is coming. Lab relocations are complex, but can be mastered with careful planning. By following nine main steps, it’s possible to ensure a successful lab move: https://hubs.li/Q02yFfb30 #labmove #science #biotech #pharma #research
9 Steps to a Successful Lab Move
go.zageno.com
To view or add a comment, sign in
-
Breaking down barriers to uncovering new drug candidates is essential for effective design and optimization of high-calibre therapeutics. Drug discovery relies heavily on expert input from diverse teams - from medicinal, synthetic, and computational chemists to biologists and drug metabolism and pharmacokinetics (DMPK) scientists. Providing specialist and unique insight, contract research organizations (CROs) can streamline the DMTA cycle and propel drug discovery processes forwards. David Bardsley and Nick Foster explore how CADD and cloud platforms help streamline drug discovery and facilitate communication, removing silos throughout the DMTA cycle, and helping organizations to make the molecules that matter. https://obi41.nl/2p82z23u #DMTA #DrugDiscovery #DrugDesign #CADD
To view or add a comment, sign in
-
-
Our team of technical and business development experts is all geared up for the upcoming Drug Discovery Chemistry conference. This presents an opportunity to engage with them and gain insights into our cutting-edge drug discovery services designed to help you accelerate your drug discovery and development initiatives. Don't miss out—schedule a meeting now by clicking on the link: https://lnkd.in/gWn76RDW At Aurigene, we specialize in the synthesis, optimization, and screening of drug candidates across various therapeutic areas. Our expertise extends to the synthesis and screening of specialized modalities such as PROTACs, peptides, steroids, PEGs, HPAPIs, and oligos, ensuring a comprehensive approach to addressing diverse research needs. For more information, write us at [email protected]. Rajeev Hotchandani Sangamesh Badiger Sreekar Reddy #DrugDiscoveryChemistry #2024 #drugdiscovery #drugdevelopment #colloboration #innovation #synthesis #screening #optimization #crdmo #aurigene
Schedule a meeting now!
aurigeneservices.com
To view or add a comment, sign in
-
SFBN Feed: AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more https://lnkd.in/gPjnb9tH Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more
https://sfbn.org
To view or add a comment, sign in
-
In the recent edition, Charting Excellence: Canada’s Top 5 Pioneers in Biotech, Insights Care is pleased to feature Starpax Biopharma, steered by its Founding President Michel Gareau, along with other biotech experts who made a difference Read More: https://bit.ly/4awDbwt #michaelgareau #StarpaxBiopharmaInc #cancertreatment #bestonlinehealthcaremagazine #healthcareinnovationmagazine
Charting Excellence: Canada’s Top 5 Pioneers in Biotech, December 2023
https://insightscare.com
To view or add a comment, sign in
-
Patient-derived cells (PDCs): the future of drug discovery Drug discovery is known for its high attrition rates that lead to significant investments in both cost and time. However, the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. In this blog, the Inaphaea team explores the potential of PDCs and their role in shaping the future of drug discovery. Read the blog here: https://bit.ly/43gvTcL #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs
To view or add a comment, sign in
-
GTM + Technical Recruiting | Executive Search | Co-Founder of Backpack Talent
3moAnother win for NC!